Post-Myocardial Infarction Management

Introduction to Beta-Blocker Therapy

• The American College of Cardiology recommends beta-blockers to reduce all-cause mortality by 23% when used after myocardial infarction in patients with coronary artery disease, and to prevent angina attacks and improve exercise tolerance in these patients 1, 2
• Beta-blockers can be used in combination with other anti-anginal medications like calcium channel blockers for better symptom control in patients with coronary artery disease 1

Indications and Recommendations for Beta-Blocker Use

• The American College of Cardiology recommends beta blockers for CAD patients with left ventricular ejection fraction (LVEF) ≤40%, with or without previous myocardial infarction (MI), due to their demonstrated mortality benefit in clinical trials 3, 4
• Beta blockers are indicated in CAD patients with LVEF <50%, specifically using sustained-release metoprolol succinate, carvedilol, or bisoprolol with titration to target doses 3, 4
• The American College of Cardiology conditionally recommends beta blockers for patients with previous STEMI (Class IIa) and recommends against beta blockers for patients with CAD without previous MI or LVEF ≤50% (Class III - not beneficial) in the absence of another primary indication 3
• The following beta blockers are recommended for patients with CAD and LVEF <50%:

3, 4, 5

Dosing and Titration

• Start with low dose and double dose at not less than 2-week intervals, aim for target dose or highest tolerated dose, and monitor heart rate, blood pressure, and clinical status, as recommended by the American College of Cardiology 5
• Monitor heart rate (target 50-60 beats/min unless side effects occur), blood pressure, and assess for signs of worsening heart failure, as recommended by the American College of Cardiology 5
• For patients with heart failure, daily weight monitoring is recommended by the American College of Cardiology 5

Contraindications and Precautions

• Absolute contraindications include asthma bronchiale, severe bronchial disease, symptomatic bradycardia or hypotension, heart block or heart rate <60/min without functioning pacemaker, as listed by the European Society of Cardiology and the American College of Cardiology 4, 5
• Relative contraindications include patients with significant chronic obstructive pulmonary disease with reactive airway component, decompensated heart failure, and diabetes, according to the American College of Cardiology and the American Heart Association 6

Duration of Therapy

• For patients with LVEF ≤40%, beta blockers should be continued indefinitely 3
• For patients initiated on beta blockers for previous MI without current LVEF ≤50%, angina, arrhythmias, or uncontrolled hypertension, it may be reasonable to reassess the indication for long-term (>1 year) use 3
• Beta blockers should be started and continued for 3 years in all patients after MI, according to the American College of Cardiology 3
• The 2023 AHA/ACC guideline represents a paradigm shift from previous practice, now recommending against routine long-term beta blocker use in stable CAD patients without specific indications like reduced LVEF, recent MI, or ongoing symptoms 3

Discontinuation and Switching

• Never abruptly discontinue beta-blockers in patients with coronary artery disease due to risk of severe exacerbation of angina, MI, and ventricular arrhythmias
• When switching between beta-blockers, start with a low dose and titrate slowly
• When switching from metoprolol to carvedilol, it is recommended to start with a low dose and titrate slowly to avoid hypotension, monitor for bradycardia, ensure the patient is hemodynamically stable, and taper metoprolol as carvedilol is being initiated 7

Perioperative Cardiovascular Protection

• Beta-blockers reduce the risk of cardiovascular events in coronary artery disease patients undergoing non-cardiac surgery 8
• Beta blockers are essential components of treatment for reducing morbidity and mortality in CAD patients, as stated by the European Heart Journal, and are recommended for secondary prevention after MI by the American College of Cardiology and the American Heart Association 9, 10, 6
• Beta blockers are effective for relieving angina symptoms, as recommended by the European Society of Cardiology 4